Latest news with #IcahnSchoolofMedicine
Business Wire
27-05-2025
- Health
- Business Wire
BeeKeeperAI Enables Icahn School of Medicine at Mount Sinai and Morehouse School of Medicine to Test the Performance of Healthcare AI Models in Their Environments
AUSTIN, Texas--(BUSINESS WIRE)--BeeKeeperAI®, Inc., a pioneer in privacy-enhancing, multi-party collaboration software for AI development and deployment, today announced that Morehouse School of Medicine (MSM) and the Icahn School of Medicine at Mount Sinai will utilize BeeKeeperAI's EscrowAI® platform to rapidly test AI models on their real-world, multi-modal data in chronic heart failure (CHF). This milestone represents the first operational deployment certified under the Coalition for Health AI (CHAI)'s assurance service provider certification process, setting a precedent for how AI models can be responsibly tested and brought to market faster across institutions and populations. 'As we advance our mission to enable responsible, evidence-based AI, this is just the first of many collaborations where CHAI-certified service providers and health institutions will work together to ensure AI serves all patients,' said Dr. Brian Anderson, CEO of CHAI. 'We're proud to see Morehouse School of Medicine, Icahn School of Medicine, and BeeKeeperAI leading the way in developing trusted AI solutions.' MSM, Icahn School of Medicine, and BeeKeeperAI are all members of CHAI and have adopted its scorecard model for algorithm developers seeking to demonstrate real-world performance to the broader market. Their shared goal is to accelerate the responsible development, validation, and market adoption of AI that improves clinical decision-making, reduces hospital readmissions, and ensures needs-based outcomes—particularly for patients with lower resource availability who face disproportionate risk from chronic heart failure. 'To bring healthcare AI to market, speed matters—but so does trust,' said Dr. Michael Blum, MD, Co-founder and CEO of BeeKeeperAI. 'With EscrowAI, Icahn School of Medicine and Morehouse School of Medicine can enable AI developers to securely test their models on high-value, real-world data in days—not months—while preserving patient privacy and model IP. This is how we unlock faster, scalable, and equitable innovation in healthcare.' The curated datasets, based on shared specifications, include clinical, demographic, and social determinants of health data—offering a rare opportunity to assess algorithm performance across institutions serving predominantly resource-limited populations. 'Morehouse School of Medicine is committed to ensuring all patients have the opportunity to achieve optimal outcomes from treatment for chronic heart failure,' said Muhammed Y. Idris, PhD, Assistant Professor, Medicine and Co-Director, Center for the Validation of Digital Health Technologies and Clinical Algorithms at Morehouse School of Medicine. 'By enabling AI developers to securely compute on our data, we're creating the foundation for algorithms that can reduce readmissions and mortality for those most at risk.' 'AI has the potential to transform clinical care delivery, but only if models are proven to be accurate, safe, and effective in real-world and diverse settings,' said Tanvir Kahlon, MD, MBA, Assistant Professor, Advanced Heart Failure and Transplant, Interventional Cardiology at Icahn School of Medicine at Mount Sinai. 'Our work with BeeKeeperAI and Morehouse makes that assurance possible—without compromising privacy or integrity.' Accelerating Trustworthy & Responsible AI with Privacy-Enhancing Technology BeeKeeperAI's EscrowAI platform allows AI model testing inside a data steward's secure environment using Trusted Execution Environments (TEEs) with confidential computing—ensuring data privacy, regulatory compliance, and protection of IP throughout the process. As a recently certified CHAI Assurance Service Provider, BeeKeeperAI meets the highest standards for ethical and secure AI validation. EscrowAI replaces lengthy data access and contracting delays with push-button, compliant testing workflows —compressing timelines and accelerating time-to-value for algorithm developers. Developers can test and prove model performance on real-world, regulated data in a SOC 2-compliant environment aligned with CHAI's data integrity and scorecard framework. The resulting performance reports are immutable, transparent, and reproducible—creating a fast, scalable path to market evaluation and adoption. CHAI Assurance: A Market-Based Model for Responsible AI This collaboration reflects a broader shift in healthcare AI—from evaluations too often based on marketing presentations to more evidence-based, transparent assurance. CHAI's conflict-of-interest and ethics policies ensure independent oversight, while BeeKeeperAI's infrastructure delivers privacy-protected reproducibility, regulatory-grade audit trails, and speed-to-deployment. Together, they support faster validation and value-based procurement for AI solutions that work, including in populations that need them most. As part of this initiative, Icahn School of Medicine and Morehouse School of Medicine will be publishing data catalogs, enabling independent AI testing and validation to support the new benchmark for healthcare AI transparency and efficiency. About BeeKeeperAI BeeKeeperAI is the pioneer in privacy-enhancing technologies, integrating Trusted Execution Environments with confidential computing to accelerate AI validation and deployment in regulated sectors, including healthcare and government. BeeKeeperAI enables real-world data to be used safely and securely, without ever exposing it—empowering institutions to bring trusted AI to market faster. Learn more at Icahn School of Medicine at Mount Sinai is an investor in BeeKeeperAI.
Mint
26-05-2025
- Health
- Mint
Why more adults than ever are being diagnosed with autism
More U.S. adults than ever before have autism, and many are being diagnosed not as children, but in later years. While the data don't pinpoint how many people are over age 18 when diagnosed, clinical psychologists say many more adults are seeking evaluations for autism than a decade ago. 'We have adults reaching out every week," said Paige Siper, chief psychologist at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai in New York. Overall, the rate of autism in people 18 or older more than doubled between 2011 and 2019, from 4.2 per 1,000 to 9.5 per 1,000, according to an analysis of Medicaid data published in the journal JAMA Psychiatry in 2023. Researchers saw the most rapid growth in adults between the ages of 26 and 34, according to a study, published in the journal JAMA Network Open in 2024, that analyzed U.S. health records and insurance claims for more than nine million individuals a year from 2011 to 2022. That group's rate of autism increased from 0.7 per 1,000 people in 2011 to 3.7 per 1,000 in 2022. Some of this growth comes from autistic children aging into adulthood. For adults seeking evaluations for the first time, scientists attribute the rise to a variety of factors. Social media has increased awareness of autism. Autism has shed the stigma it used to hold. The definition of the condition has expanded over time to include a broader range of behaviors. And some parents who have children diagnosed with autism then recognize their own challenges and seek out evaluations, said Michelle Gorenstein-Holtzman, a clinical psychologist who works with adults at the NewYork-Presbyterian/Weill Cornell Medical Center and the Center for Autism and the Developing Brain. Three years ago, before she joined, the center did one adult autism evaluation a month. Now Gorenstein-Holtzman does two a week. People diagnosed as adults typically don't have severe communication challenges or intellectual disabilities, clinical psychologists said. But they have struggled socially, and show subtle repetitive behaviors like rocking in a chair, or nearly obsessive interests in certain topics. They often have other continuing mental-health conditions, such as anxiety, bipolar disorder or ADHD. Many are highly educated, and some have successful careers, though some have been in and out of jobs. Many are women whose autism was missed when they were children, said Catherine Lord, a clinical psychologist and autism researcher at the David Geffen School of Medicine at UCLA. About three times as many boys are diagnosed with autism as girls, partly because some of the behaviors psychologists look for are less pronounced in girls, and partly because researchers have been trained to better recognize the condition in boys. Growing up, Sonia Chand said she felt out of touch with her peers and judged by teachers and therapists. 'I was made to feel like I was the bad kid," she said. 'I wasn't trying to act up in a bad way. I was just trying to fit in." Sonia Chand and her parents, Kishan Chand and Krishna Pahuja, looking at photos up, Chand said, she felt misunderstood and rejected by her peers, teachers and therapists. In sixth grade, she was diagnosed with depression, prescribed lithium and flagged at risk for suicide. At age 20, after a new therapist had heard her story and referred her for an advanced neuropsychological evaluation, she was diagnosed with Asperger's in 2002. Now 42, she works as a therapist herself, runs marathons and hosts a podcast in her free time. At the time Chand was diagnosed, Asperger's syndrome was considered a developmental disorder in which people had trouble with social interactions but didn't have language delays or cognitive impairments associated with autism. Autism first appeared as a distinct diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, a standardized classification system for mental disorders, in 1980. Initially, the diagnosis required children by age 2.5 years to exhibit a narrow set of behaviors that typically applied only to those with severe disabilities. Each subsequent edition of the manual has broadened the definition of the condition, said David Mandell, director of the Penn Center for Mental Health at the University of Pennsylvania. In 2013, Asperger's and other developmental disorders were included under the category of autism spectrum disorder, which acknowledged varying levels of severity—and helped to pave the way for more diagnoses in adults. Chand now works as a licensed professional counselor and hosts a podcast.. Holden Thorp, editor in chief of the Science family of journals, was in his 50s when a psychologist evaluating senior administrators at Washington University in St. Louis, where he was provost, told him he was autistic in 2016. Thorp had established himself as a research scientist, climbed the ranks of university leadership and served as chancellor of the University of North Carolina at Chapel Hill. 'A lot of things came together all at once," Thorp said, ranging from his habit of staring at a wall when people were talking to him to student evaluations that said he was 'a great teacher" but 'very monotone." Now, he tells classes on the first day that he's on the spectrum and explains that expressive intonations or big arm gestures are a challenge. 'That was very liberating," he said. Some adults welcome the diagnosis as a way to make sense of the challenges they have faced all their lives. 'When I started in the field, everyone's vision of autism was more like Rain Man," said Gorenstein-Holtzman. 'Now, I think people have more ideas of what autism could look like." Write to Nidhi Subbaraman at
Medscape
21-05-2025
- Health
- Medscape
Blood Test May Predict Crohn's Disease 2 Years Before Onset
SAN DIEGO — Crohn's disease (CD) has become more common in the United States, and an estimated 1 million Americans have the condition. Still, much is unknown about how to evaluate the individual risk for the disease. 'It's pretty much accepted that Crohn's disease does not begin at diagnosis,' said Ryan Ungaro, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, New York City, speaking at Digestive Disease Week (DDW) 2025. Although individual blood markers have been associated with the future risk for CD, what's needed, he said, is to understand which combination of biomarkers are most predictive. Now, Ungaro and his team have developed a risk score they found accurate in predicting CD onset within 2 years before its onset. It's an early version that will likely be further improved and needs additional validation, Ungaro told Medscape Medical News . 'Once we can accurately identify individuals at risk for developing Crohn's disease, we can then imagine a number of potential interventions,' Ungaro said. Approaches would vary depending on how far away the onset is estimated to be. For people who likely wouldn't develop disease for many years, one intervention might be close monitoring to enable diagnosis in the earliest stages, when treatment works best, he said. Someone at a high risk of developing CD in the next 2 or 3 years, on the other hand, might be offered a pharmaceutical intervention. Developing and Testing the Risk Score To develop the risk score, Ungaro and colleagues analyzed data of 200 patients with CD and 100 healthy control participants from PREDICTS, a nested case-controlled study of active US military service members. The study is within the larger Department of Defense Serum Repository, which began in 1985 and has more than 62.5 million samples, all stored at −30 °C. The researchers collected serum samples at four timepoints up to 6 or more years before the diagnosis. They assayed antimicrobial antibodies using the Prometheus Laboratories platform, proteomic markers using the Olink inflammation panel, and anti–granulocyte macrophage colony-stimulating factor autoantibodies using enzyme-linked immunosorbent assay. Participants (median age, 33 years for both groups) were randomly divided into equally sized training and testing sets. In both the group, 83% of patients were White and about 90% were men. Time-varying trajectories of marker abundance were estimated for each biomarker. Then, logistic regression modeled disease status as a function of each marker for different timepoints and multivariate modeling was performed via logistic LASSO regression. A risk score to predict CD onset within 2 years was developed. Prediction models were fit on the testing set and predictive performance evaluated using receiver operating characteristic curves and area under the curve (AUC). Blood proteins and antibodies have differing associations with CD depending on the time before diagnosis, the researchers found. The integrative model to predict CD onset within 2 years incorporated 10 biomarkers associated significantly with CD onset. The AUC for the model was 0.87 (considered good, with 1 indicating perfect discrimination). It produced a specificity of 99% and a positive predictive value of 84%. The researchers stratified the model scores into quartiles and found the CD incidence within 2 years increased from 2% in the first quartile to 57.7% in the fourth. The relative risk of developing CD in the top quartile individuals vs lower quartile individuals was 10.4. The serologic and proteomic markers show dynamic changes years before the diagnosis, Ungaro said. A Strong Start The research represents 'an ambitious and exciting frontier for the future of IBD [inflammatory bowel disease] care,' said Victor G. Chedid, MD, MS, consultant and assistant professor of medicine at Mayo Clinic, Rochester, Minnesota, who reviewed the findings but was not involved in the study. Currently, physicians treat IBD once it manifests, and it's difficult to predict who will get CD, he said. The integrative model's AUC of 0.87 is impressive, and its specificity and positive predictive value levels show it is highly accurate in predicting the onset of CD within 2 years, Chedid added. Further validation in larger and more diverse population is needed, Chedid said, but he sees the potential for the model to be practical in clinical practice. 'Additionally, the use of blood-based biomarkers makes the model relatively noninvasive and easy to implement in a clinical setting,' he said. Now, the research goal is to understand the best biomarkers for characterizing the different preclinical phases of CD and to test different interventions in prevention trials, Ungaro told Medscape Medical News . A few trials are planned or ongoing, he noted. The trial PIONIR trial will look at the impact of a specific diet on the risk of developing CD, and the INTERCEPT trial aims to develop a blood-based risk score that can identify individuals with a high risk of developing CD within 5 years after initial evaluation. Ungaro reported being on the advisory board of and/or receiving speaker or consulting fees from AbbVie, Bristol Myer Squibb, Celltrion, ECM Therapeutics, Genentech, Jansen, Eli Lilly, Pfizer, Roivant, Sanofi, and Takeda. Chedid reported having no relevant disclosures.
Jordan News
14-05-2025
- Health
- Jordan News
Niacinamide to the Rescue: How to Use It for Tired, Stressed-Out Skin - Jordan News
Niacinamide isn't Botox, but it can still work wonders for your skin. This vitamin B3 derivative helps calm redness, soothe acne-related irritation, and even strengthen your skin barrier, making it more resilient to harmful external factors. اضافة اعلان The best part? You can find it in most beauty stores in the form of serums or creams—no injections needed. Despite its powerful ability to address many skin concerns, it's gentle enough for all skin types. Still not sure if you should add niacinamide to your skincare routine? Keep reading to learn how this skin-saving ingredient can transform your complexion. What Is Niacinamide? Niacinamide is a form of niacin, also known as vitamin B3. According to dermatologist Dr. Jennifer MacGregor, it's made up of vitamin B3 and nicotinic acid. In the body, vitamin B3 supports metabolism and aids in vital functions—from lowering bad cholesterol to detoxifying the liver. On the skin, niacinamide acts as a potent anti-inflammatory agent, says Dr. MacGregor of Union Square Laser Dermatology in New York. What Are the Benefits of Using Niacinamide? If your skin is red, irritated, or uneven (due to sensitivity, acne, or rosacea), niacinamide can help calm inflammation, Dr. MacGregor explains. It's also a great addition to any anti-aging routine because it helps repair the skin barrier—the layer that keeps moisture in and bacteria out—leaving your skin better hydrated. More hydration = plumper, brighter skin with less noticeable fine lines. According to Dr. Debra Jaliman, Assistant Professor of Dermatology at the Icahn School of Medicine in New York, niacinamide can also gently brighten dull skin, fade dark spots from sun damage or acne, and improve uneven texture (like large pores). And if that's not enough, niacinamide plays nicely with most skincare ingredients, including retinol, alpha hydroxy acids, and antioxidants like vitamin C—making it easy to layer into your routine without worrying about adverse reactions. How Should I Use Niacinamide? Dr. Jaliman recommends using a day or night cream that contains niacinamide for optimal results. You can also mix a few drops of a niacinamide serum into your daily moisturizer. Dr. MacGregor also suggests getting your niacinamide through your sunscreen, if it's included in the formula. Niacinamide is gentle enough to be used twice daily—morning and night—and fits seamlessly into any regular skincare routine. For best results, apply it right after cleansing and before moisturizer or facial oils, according to Women's Health Magazine. Morning Routine: After cleansing, apply a serum with 5–10% niacinamide. Follow up with your regular moisturizer and sunscreen (especially if heading outdoors). In the morning, niacinamide helps support the skin's natural barrier and reduces the impact of pollution and UV rays—especially when included in sunscreen formulas. Evening Routine: Apply niacinamide serum after cleansing, before your night cream or nourishing oils. In the evening, it works to repair irritated skin, fade hyperpigmentation, and calm redness from acne or dryness. Pro Tips: You can safely combine it with ingredients like retinol, hyaluronic acid, or vitamin C, as it's a gentle, non-reactive compound. Start with a low concentration (around 5%) if you have sensitive skin, then increase as tolerated. Avoid introducing too many new products at once—give your skin time to adjust to niacinamide. In short: Niacinamide is a multitasking skincare hero. Whether you're dealing with redness, dryness, acne, or signs of aging, it deserves a place in your daily regimen.
Yahoo
13-05-2025
- Health
- Yahoo
Mount Sinai Health System to Honor Dennis S. Charney, MD, Dean of the Icahn School of Medicine at Mount Sinai, for 18 Years of Leadership and Service at Annual Crystal Party
Will retire at the end of his current term on June 30; Eric J. Nestler, MD, PhD, appointed interim dean New York, NY, May 13, 2025 (GLOBE NEWSWIRE) -- Mount Sinai Health System announced today that it will recognize Dennis S. Charney, MD, the outgoing Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, for 18 years of leadership and service at its 40th annual Crystal Party, Tuesday, May 20, at Pier Sixty, 60 Chelsea Piers. Dr. Charney is one of the longest-serving deans of any medical school nationwide and will step down as Dean on Monday, June 30. He will remain on the faculty at the Icahn School of Medicine at Mount Sinai to continue his research and teaching. Dr. Charney, a preeminent expert in neurobiology who has made fundamental contributions to the understanding of human anxiety, fear, depression, and resilience, has played a key role in the discovery of new treatments for mood and anxiety disorders. He was recently named one of the 2025 TIME 100 Health Most Influential People in Health for his breakthrough treatments for depression. 'It has been my immense pleasure to lead this school and to be entrusted with shaping the vision and mission that has elevated Mount Sinai's standing in academic medicine,' said Dr. Charney. 'None of that would have been possible without the contributions of our faculty, staff, and students, all of whom have made serving the Icahn School of Medicine at Mount Sinai the greatest joy of my professional life. I look forward to seeing how the School will build on what we have created together.' Under Dr. Charney's leadership, the Icahn School of Medicine at Mount Sinai has advanced its reputation as an international leader in biomedical, scientific, and public health education, research, and clinical care. He recruited brilliant faculty members across the biomedical sciences, computational biology, and information technology, fostering a culture of innovation and scientific risk-taking. He also established more than two dozen interdisciplinary research institutions, fueling collaborations and investigations that have resulted in life-changing breakthroughs in the diagnosis and treatment of cancer, heart disease, gastrointestinal disease, and psychiatric illness. In addition to these achievements, Dr. Charney achieved dramatic growth in funding from the National Institutes of Health, which reached half a billion dollars in annual support in 2024, placing the Icahn School of Medicine at Mount Sinai No. 11 among medical schools and in the 99th percentile among U.S. private medical schools for research funding per principal investigator. He built the Icahn School of Medicine at Mount Sinai into the largest graduate medical program in the country, with more than 2,600 residents and clinical fellows. He also established partnerships with the Hasso Plattner Institute, Rensselaer Polytechnic Institute, and the State University of New York at Stony Brook to develop digital health products that are advancing precision medicine for the benefit of patients around the world. Dr. Charney was elected to the National Academy of Medicine in 2000 and has been honored with every major award in his field for his scientific research. He received the Colvin Prize for Outstanding Achievement in Mood Disorder Research in 2019 and the Rhoda & Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine in 2023. He is a co-inventor of Ketamine, a rapidly acting US Food and Drug Administration (FDA)-approved antidepressant marketed as SPRAVATO™, has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. He is also the co-inventor of the first prescription digital therapeutic, marketed as Rejoyn, and approved by FDA for the treatment of major depressive disorder (MDD). 'Dennis Charney's legacy as one of the greatest transformational leaders in the history of academic medicine is well established and impressive. Through his efforts, he has put in place the people and resources that will ensure that the Icahn School of Medicine continues to excel in our mission to educate and train the physicians and scientists who will develop cutting-edge medical approaches to the greatest health challenges we face. We are grateful for all he has done for the School and the Health System,' said Brendan G. Carr, MD, MA, MS, Chief Executive Officer and Kenneth L. Davis, MD, Distinguished Chair of the Mount Sinai Health System. 'I always knew Dennis Charney would be a transformative leader,' said Kenneth L. Davis, MD, Executive Vice Chairman, Boards of Trustees, and former President and CEO, Mount Sinai Health System. 'His outside-the-box thinking, not restricted by tradition or a traditional leadership philosophy, and his thoughtfulness and strength would make him a steady leader to guide the School to greatness. He created a unique place of learning, teaching, and research, and I have been proud to be his partner and friend on this journey.' 'Dennis Charney is a visionary leader who has transformed the Icahn School of Medicine by creating an entrepreneurial capability inside our school where clinical and basic science research innovation thrive,' said Richard A. Friedman and James S. Tisch, Co-Chairs of the Mount Sinai Health System Boards of Trustees. 'He will be remembered as a pioneer who found a new bold and successful strategy for our school.' Eric J. Nestler, MD, PhD, has been appointed Interim Dean of the Icahn School of Medicine at Mount Sinai. One of the world's leading experts on the molecular mechanisms of drug addiction and depression, Dr. Nestler has been Dean for Academic Affairs of the Icahn School of Medicine and Chief Scientific Officer of the Mount Sinai Health System since 2016. He has authored more than 750 publications and five books, and his work has been recognized with the Wilbur Cross Distinguished Alumnus Medal from Yale University and the Peter Seeburg Prize in Integrative Neuroscience from the Society for Neuroscience. He has been a member of the National Academy of Medicine since 1998 and was recently elected to the National Academy of Sciences, one of the highest honors that a scientist can achieve, recognizing individuals for their distinguished and continuing achievements in original research. About the Mount Sinai Health System Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients' medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek's® 'The World's Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals' and by U.S. News & World Report's® 'Best Hospitals' and 'Best Children's Hospitals.' The Mount Sinai Hospital is on the U.S. News & World Report® 'Best Hospitals' Honor Roll for 2024-2025. For more information, visit or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. CONTACT: Mount Sinai Press Office Mount Sinai Press Office newsmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
